These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21468051)

  • 1. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening.
    Pashayan N; Duffy SW; Chowdhury S; Dent T; Burton H; Neal DE; Easton DF; Eeles R; Pharoah P
    Br J Cancer; 2011 May; 104(10):1656-63. PubMed ID: 21468051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of polygenic risk for personalised colorectal cancer screening.
    Frampton MJ; Law P; Litchfield K; Morris EJ; Kerr D; Turnbull C; Tomlinson IP; Houlston RS
    Ann Oncol; 2016 Mar; 27(3):429-34. PubMed ID: 26578737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic susceptibility to testicular cancer: implications for personalised health care.
    Litchfield K; Mitchell JS; Shipley J; Huddart R; Rajpert-De Meyts E; Skakkebæk NE; Houlston RS; Turnbull C
    Br J Cancer; 2015 Nov; 113(10):1512-8. PubMed ID: 26461055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    Wong XY; Chong KJ; van Til JA; Wee HL
    BMC Cancer; 2017 Nov; 17(1):776. PubMed ID: 29162038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalised medicine and population health: breast and ovarian cancer.
    Narod SA
    Hum Genet; 2018 Oct; 137(10):769-778. PubMed ID: 30328515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.
    Mühlberger N; Boskovic K; Krahn MD; Bremner KE; Oberaigner W; Klocker H; Horninger W; Sroczynski G; Siebert U
    BMC Public Health; 2017 Jun; 17(1):596. PubMed ID: 28651567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based screening in the era of genomics.
    Pashayan N; Pharoah P
    Per Med; 2012 Jun; 9(4):451-455. PubMed ID: 22984365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening.
    Byrne L; Toland AE
    Urol Clin North Am; 2021 Aug; 48(3):387-399. PubMed ID: 34210493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cases in Precision Medicine: The Role of Polygenic Risk Scores in Breast Cancer Risk Assessment.
    Zeinomar N; Chung WK
    Ann Intern Med; 2021 Mar; 174(3):408-412. PubMed ID: 33253037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family history and prostate cancer screening with prostate-specific antigen.
    Mäkinen T; Tammela TL; Stenman UH; Määttänen L; Rannikko S; Aro J; Juusela H; Hakama M; Auvinen A
    J Clin Oncol; 2002 Jun; 20(11):2658-63. PubMed ID: 12039927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for common genomic variants in the assessment of familial breast cancer.
    Sawyer S; Mitchell G; McKinley J; Chenevix-Trench G; Beesley J; Chen XQ; Bowtell D; Trainer AH; Harris M; Lindeman GJ; James PA
    J Clin Oncol; 2012 Dec; 30(35):4330-6. PubMed ID: 23109704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women's responses and understanding of polygenic breast cancer risk information.
    Yanes T; Kaur R; Meiser B; Scheepers-Joynt M; McInerny S; Barlow-Stewart K; Antill Y; Salmon L; Smyth C; James PA; Young MA
    Fam Cancer; 2020 Oct; 19(4):297-306. PubMed ID: 32430685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and pilot testing of a leaflet informing women with breast cancer about genomic testing for polygenic risk.
    Kaur R; Meiser B; Yanes T; Young MA; Barlow-Stewart K; Roscioli T; Smith S; James PA
    Fam Cancer; 2019 Apr; 18(2):147-152. PubMed ID: 30251170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.
    Gulati R; Cheng HH; Lange PH; Nelson PS; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):222-227. PubMed ID: 27742670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving breast cancer screening in Australia: a public health perspective.
    Nickson C; Velentzis LS; Brennan P; Mann GB; Houssami N
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current controversies in screening: cholesterol, breast cancer, and prostate cancer.
    Sox HC
    Mt Sinai J Med; 1999 Mar; 66(2):91-101. PubMed ID: 10100412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.